Children with HIV: Improved mortality and morbidity with combination antiretroviral therapy

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 253-259

  Foster, Caroline ^a   Lyall, E G Hermione ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; Paediatrics

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; MULTIVITAMIN; NELFINAVIR; RETINOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADOLESCENT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG BLOOD LEVEL; EVIDENCE BASED MEDICINE; GENOTYPE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; MORBIDITY; MORTALITY; NEUROPROTECTION; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; REVIEW; TOXICITY; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS TRANSMISSION;

EID: 20044390552     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168387.24142.cf     Document Type: Review

References (61)

1. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:442-450.
2. European Collaborative Study. Gender and race do not alter early-life determinants of clinical disease progression in HIV-1 vertically infected children. AIDS 2004; 18:509-516.
3. Dunn D. HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-Infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1595-1596.
4. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J 2003; 22:635-641.
5. Gibb DM, Duong T, Tookey PA, et al. National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.
6. Cooper S, Lyall H, Walters S, et al. Children with human immunodeficiency virus admitted to a paediatric intensive care unit in the United Kingdom over a 10-year period. Intensive Care Med 2004; 30:113-118.
7. Faye A, Le Chenadec J, Dollfus C, et al. French Perinatal Study Group. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39:1692-1698.
8. Abrams EJ, Wiener J, Carter R, et al. Perinatal AIDS Collaborative Transmission Study (PACTS) Group. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003; 17:867-877.
9. Ioannidis JP, Tatsioni A, Abrams EJ, et al. Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis. AIDS 2004; 18:99-108.
10. Kuhn L, Abrams EJ, Palumbo P, et al. Perinatal AIDS Collaborative Transmission Study. Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression. AIDS 2004; 18:1281-1289.
11. Feeney ME, Roosevelt KA, Tang Y, et al. Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CDS responses in perinatally infected children. J Virol 2003; 77:7492-7501.
12. Feeney ME, Tang Y, Roosevelt KA, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004; 78:8927-8930.
13. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:229-230.
14. Sandberg JK, Fast NM, Jordan KA, et al. HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol 2003; 170:4403-4410.
15. Borkowsky W, Zhan MX, Chen SH, et al. Correlation between HIV-specific CD8 cell production of interferon-gamma and plasma levels of HIV RNA in perinatally infected pediatric populations. J Infect Dis 2004; 190:722-726.
16. Feeney ME, Draenert R, Roosevelt KA, et al. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol 2003; 171:6968-6975.
17. Hazenberg MD, Otto SA, van Rossum AMC, et al. Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1. Blood 2004; 104:3513-3519.
18. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. HIV Host Genetics International Meta-Analysis Group. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 2003; 17:1631-1638.
19. Singh KK, Barroga CF, Hughes MD, et al. Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States. J Acquir Immune Defic Syndr 2004; 35:309-313.
20. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis 2003; 188:1461-1472.
21. Newell ML, Coovadia H, Cortina-Borja M, et al. Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243. Important metaanalysis demonstrating very high mortality in HIV-infected and uninfected children born to HIV-infected mothers in Africa, at 2 years of age 52.5% and 7.6%, respectively.
22. Brahmbhatt H, Gray RH. Child mortality associated with reasons for non-breastfeeding and weaning: is breastfeeding best for HIV-positive mothers? AIDS 2003; 17:879-885.
23. Coutsoudis A, Pillay K, Spooner E, et al. Morbidity in children born to women infected with human immunodeficiency virus in South Africa: does mode of feeding matter? Acta Paediatr 2003; 92:890-895.
24. Farquhar C, Rowland-Jones S, Mbori-Ngacha D, et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses 2004; 20:692-697.
25. Villamor E, Misegades L, Fataki MR, et al. Child mortality in relation to HIV infection, nutritional status, and socio-economic background. Int J Epidemiol 2005; 13 January [Epub ahead of print].
26. Villamor E, Fataki MR, Bosch RJ, et al. Human immunodeficiency virus infection, diarrheal disease and sociodemographic predictors of child growth. Acta Paediatr 2004; 93:372-379.
27. Shahab T, Zoha MS, Malik MA, et al. Prevalence of human immunodeficiency virus infection in children with tuberculosis. Indian Pediatr 2004; 41:595-599.
28. Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365:130-134.
29. Pillay T, Khan M, Moodley J, et al. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis 2004; 4:155-165.
30. Chintu C, Bhat GJ, Walker AS, et al. CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-1871. Randomized controlled study demonstrating a significant protective effect of co-trimoxazole on mortality and morbidity in HIV-infected children in Africa.
31. Mofenson LM, Oleske J, Serchuck L, et al. CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1-92.
32. Stins MF, Pearce D, Di Cello F, et al. Induction of intercellular adhesion molecule-1 on human brain endothelial cells by HIV-1 gp120: role of CD4 and chemokine coreceptors. Lab Invest 2003; 83:1787-1798.
33. McCoig C, Castrejon MM, Saavedra-Lozano J, et al. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23:114-118.
34. Sanchez-Ramon S, Bellon JM, Resino S, et al. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Pediatrics 2003; 111 :E168-E175.
35. Sanchez-Ramon S, Resino S, Bellon Cano JM, et al. Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatr Neural 2003; 29:218-221.
36. Faye A, Le Chenadec J, Dollfus C, et al. French Perinatal Study Group. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39:1692-1698.
37. Sharland M, Blanche S, Castelli G, et al. PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5(Suppl 2): 61-86.
38. Luzuriaga K, McManus M, Mofenson L, et al. PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004; 350:2471-2480.
39. Aboulker JP, Babiker A, Chaix ML, et al. Paediatric European Network for Treatment of AIDS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18:237-245. Long-term follow-up data for infants on nelfinavir showing high levels of virological failure and resistance highlighting the difficulties of ART prescribing in infancy.
40. Bergshoeff AS, Fraaij PLA, van Rossum AMC, et al. Pharmokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Therapy 2003; 8:215-222.
41. Burger DM, Bergshoeff AS, De Groot R, et al. PENTA 5 study group. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J Pediatr 2034; 145:403-405.
42. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17:1639-1647.
43. Walker AS, Doerholt K, Sharland M, Gibb DM. Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924. Emphasizes the need for age-determined ART prescribing and parallels variations with immunoreconstitution at differing ages.
44. Nikolic-Djokic D, Essajee S, Rigaud M, et al. Immunoreconstit-Jtion in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis 2002; 185:290-298.
45. Machado ES, Lambert JS, Watson DC, et al. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. J Clin Virol 2004; 30:24-31.
46. Englund JA, Raskino C, Vavro C, et al. Pediatric AIDS Clinical Trials Group Protocol 152 Team. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 2004; 23:15-22.
47. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-979. Having an 'undetectable' viral load is dependent on the sensitivity of the assay and most children appear to have circulating virus at very low levels (<50 RNA c/ml), the long-term implications of which require clarification.
48. Soh CH, Oleske JM, Brady MT, et al. Pediatric AIDS Clinical Trials Group. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362:2045-2051.
49. Plipat N, Ruan PK, Fenton T, Yogev R. Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART. J Virol 2004; 78:11272-11275.
50. Church JA, Hughes M, Chen J, et al. Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuYirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004; 23:713-718.
51. Fawzi WW, Msamanga GI, Wei R, et al. Effect of providing vitamin supplements to human immunodeficiency virus-infected, lactating mothers on the child's morbidity and CD4+ cell counts. Clin Infect Dis 2003; 36:1053-1062.
52. Eley B, Nuttall J, Davies MA, et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J 2004; 94:643-646.
53. Kline MW, Matusa RF, Copaciu L, et el. Comprehensive pediatric human immunodeficiency virus care and treatment in Constanta, Romania: implementation of a program of highly active antiretroviral therapy in a resource-poor setting. Pediatr Infect Dis J 2004; 23:695-700.
54. Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26:122-126.
55. Brundage RC, Yong FH, Fenton T, et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004; 48:979-984. Interpatient variability due to genetic variations in drug metabolism is well recognized but intrapatient variability and its significance are less well characterized.
56. Marhefka SL, Parley JJ, Rodrigue JR, et al. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). AIDS Care 2004; 16:323-338.
57. Gibb DM, Duong T, Leclezio VA, et al. Collaborative HIV Paediatric Study Steering Committee. Immunologic changes during unp anned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2004; 23:446-450. This study approximates the rate of fall of CD4% in children after cessation of ART and is necessary for studies of planned treatment interruptions such as PENTA 11.
58. European Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
59. Bonnet D, Aggoun Y, Szezepanski I, ef al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18:1037-1041.
60. Misdrahi D, Vila G, Funk-Brentano I, et al. DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1). Eur Psychiatry 2004; 19:182-184.
61. Flynn PM, Rudy BJ, Douglas SD, et al. Pediatric AIDS Clinical Trial Group 381 Study Team. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004; 190:271-279.